Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Roche Holdings Ltd ADR (RHHBY)

Roche Holdings Ltd ADR (RHHBY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 282,226,272
  • Shares Outstanding, K 6,848,490
  • Annual Sales, $ 64,165 M
  • Annual Income, $ 13,585 M
  • 60-Month Beta 0.32
  • Price/Sales 4.56
  • Price/Cash Flow 12.90
  • Price/Book 7.82
Trade RHHBY with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 04/22/20
  • Annual Dividend & Yield 0.72 (1.74%)
  • Most Recent Dividend 0.719 on 03/19/20
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.3800 +0.20%
on 10/28/20
44.2700 -8.61%
on 10/12/20
-3.6500 (-8.27%)
since 09/28/20
3-Month
40.3800 +0.20%
on 10/28/20
47.1500 -14.19%
on 09/18/20
-4.0200 (-9.04%)
since 07/28/20
52-Week
35.0400 +15.47%
on 03/23/20
47.1500 -14.19%
on 09/18/20
+3.4400 (+9.29%)
since 10/28/19

Most Recent Stories

More News
Novartis' (NVS) Q3 Earnings Surpass Estimates, Sales Miss

Novartis' (NVS) third-quarter 2020 sales take a hit due to the coronavirus pandemic but earnings beat estimates.

JNJ : 138.43 (-3.30%)
RHHBY : 40.2560 (-2.31%)
NVS : 78.73 (-2.74%)
ABBV : 80.39 (-2.80%)
Roche (RHHBY) Inks Deal to Develop Oral Coronavirus Treatment

Roche (RHHBY) signs a contract with privately-held Atea Pharmaceuticals for jointly developing AT-527, an oral treatment for COVID-19 patients.

RHHBY : 40.2560 (-2.31%)
LLY : 131.92 (+0.02%)
GSK : 34.01 (-3.79%)
VIR : 33.12 (-6.78%)
Amgen (AMGN) to Report Q3 Earnings: What's in the Cards?

Investors will focus on whether Amgen's (AMGN) sales have recovered in the third quarter from the COVID-19 effect.

RHHBY : 40.2560 (-2.31%)
INCY : 85.73 (-2.97%)
BMY : 57.66 (-1.84%)
AMGN : 216.83 (-2.97%)
Prothena (PRTA) to Advance Parkinson's Disease Drug to Phase II

Prothena (PRTA) and partner Roche (RHHBY) plan to advance prasinezumab into a phase IIb study in patients with early Parkinson's disease.

RHHBY : 40.2560 (-2.31%)
BMY : 57.66 (-1.84%)
EBS : 92.08 (-2.96%)
PRTA : 11.13 (-3.13%)
AstraZeneca's (AZN) Tagrisso sNDA Receives Priority Review

AstraZeneca's (AZN) regulatory application for label expansion of Tagrisso to include adjuvant treatment of patients with early-stage EGFR-mutated lung cancer gets FDA's apriority review.

AZN : 51.30 (-2.25%)
RHHBY : 40.2560 (-2.31%)
MRK : 76.35 (-2.10%)
VRTX : 210.14 (-0.97%)
Biogen (BIIB) Q3 Earnings Top, Tecfidera Generics Hurt Sales

Biogen (BIIB) beats third-quarter estimates for both earnings and sales. Tecfidera generics hurts sales, resulting in guidance cut.

BIIB : 248.33 (-2.73%)
JNJ : 138.43 (-3.30%)
RHHBY : 40.2560 (-2.31%)
MYL : 14.05 (-2.84%)
Aptose (APTO) Initiates Phase I a/b Study in Leukemia Patients

Aptose (APTO) doses first patient with acute myeloid leukemia in a phase I a/b study with CG-806, with a starting dose of 450 mg.

RHHBY : 40.2560 (-2.31%)
EBS : 92.08 (-2.96%)
ABBV : 80.39 (-2.80%)
APTO : 4.46 (-5.11%)
Bristol-Myers' (BMY) Opdivo Gets Positive CHMP View for ESCC

The CHMP passes a favorable opinion for the approval of Bristol-Myers' (BMY) Opdivo to address advanced/ metastatic esophageal squamous cell carcinoma in the EU.

AZN : 51.30 (-2.25%)
RHHBY : 40.2560 (-2.31%)
MRK : 76.35 (-2.10%)
BMY : 57.66 (-1.84%)
Roche (RHHBY), AbbVie's Leukemia Drug Venclexta Get Full FDA Nod

Roche (RHHBY) and partner AbbVie obtain full FDA approval for leukemia drug, Venclexta, in combination with Vidaza or Dacogen or low-dose cytarabine (LDAC).

REGN : 564.54 (-3.09%)
SNY : 46.20 (-2.53%)
RHHBY : 40.2560 (-2.31%)
ABBV : 80.39 (-2.80%)
Biogen (BIIB) to Report Q3 Earnings: What's in the Cards?

Investor focus is likely to be on sales numbers of Tecfidera and Spinraza when Biogen (BIIB) reports third-quarter earnings.

BIIB : 248.33 (-2.73%)
RHHBY : 40.2560 (-2.31%)
MRK : 76.35 (-2.10%)
VRTX : 210.14 (-0.97%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strongest short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Key Turning Points

2nd Resistance Point 41.8300
1st Resistance Point 41.5200
Last Price 40.2560
1st Support Level 41.0200
2nd Support Level 40.8300

See More

52-Week High 47.1500
Fibonacci 61.8% 42.5240
Fibonacci 50% 41.0950
Last Price 40.2560
Fibonacci 38.2% 39.6660
52-Week Low 35.0400

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar